Boston Scientific Reports Global Disruption After Cybersecurity Incident
Boston Scientific reports a cyber incident disrupting global operations, limiting system access and affecting order processing and shipments.
Read original at benzingaStocks · News reference
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3 impairment.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 1:32 PM
- Checked
- Jul 31, 2026, 1:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
Read original at benzingaHims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
Hims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 drug prices and reveals in-house AI plans.
Read original at benzinga'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ
https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2
Read original at benzinga